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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United
States, suggesting that novel strategies for the prevention and treatment of PDAC are urgently needed. K-ras mutations are
observed in .90% of pancreatic cancer, suggesting its role in the initiation and early developmental stages of PDAC. In
order to gain mechanistic insight as to the role of mutated K-ras, several mouse models have been developed by targeting a
conditionally mutated K-ras
G12D for recapitulating PDAC. A significant co-operativity has been shown in tumor development
and metastasis in a compound mouse model with activated K-ras and Ink4a/Arf deficiency. However, the molecular
mechanism(s) by which K-ras and Ink4a/Arf deficiency contribute to PDAC has not been fully elucidated.
Methodology/Principal Findings: To assess the molecular mechanism(s) that are involved in the development of PDAC in
the compound transgenic mice with activated K-ras and Ink4a/Arf deficiency, we used multiple methods, such as Real-time
RT-PCR, western blotting assay, immunohistochemistry, MTT assay, invasion, EMSA and ELISA. We found that the deletion of
Ink4a/Arf in K-ras
G12D expressing mice leads to PDAC, which is in part mediated through the activation of Notch and NF-kB
signaling pathways. Moreover, we found down-regulation of miR-200 family, which could also play important roles in tumor
development and progression of PDAC in the compound transgenic mice.
Conclusions/Significance: Our results suggest that the activation of Notch and NF-kB together with the loss of miR-200
family is mechanistically linked with the development and progression of PDAC in the compound K-ras
G12D and Ink4a/Arf
deficient transgenic mice.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a highly
aggressive malignant disease, which is ranked as the fourth
leading cause of cancer-related death with a median survival of 6
months, and with an estimated 43,140 newly diagnosed cases and
an approximately 36,800 deaths in the United States in 2010 [1].
It has been accepted that the development of PDAC occurs
through the progression of precursor lesions such as pancreatic
intraepithelial neoplasia (PanIN), ranging from low-grade PanINs
(PanIN-1A, PanIN-1B) to high-grade PanINs (PanIN-2, PanIN-3)
[2,3]. PDAC has been shown to have multi-step molecular
progression including high frequency of activating K-ras
mutations and subsequent inactivation of p16
INK4a,p 5 3 ,
SMAD4, p14ARF tumor suppressors and other additional
genetic abnormalities in mouse models [4–6] and in human
[7]. The most common K-ras mutation in human PDAC is on
codon 12 (Kras
G12D), which is related to the activation of GTPase
activity. Therefore, several mouse models of PDAC have been
generated by targeting a conditionally mutated K-ras
G12D to
recapitulate the progression of PDAC [8–12]. One compound
mouse model containing activated K-ras and Ink4a/Arf defi-
ciency showed to cooperate in producing metastatic PDAC
[13,14]. However, the molecular mechanism(s) by which
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aggressiveness has not been fully elucidated.
In recent years, many signaling pathways including Notch
pathway have been investigated and found to play important roles
in PDAC [15]. Notch signaling has critical functions on the control
of cell growth, differentiation, apoptosis, migration, invasion, and
metastasis in PDAC [16]. Notch genes encode proteins which can
be activated by interacting with a family of its ligands. To date, four
Notch receptors (Notch1–4) and five ligands (Dll-1, Dll-3, Dll-4,
Jagged-1, Jagged-2) have been identified [17]. Interestingly, it has
been reported that the function of Notch signaling in tumorigenesis
can be either oncogenic or oncosuppressive, and the function is also
context dependent in PDAC [18,19]. Notch signaling is frequently
deregulated with up-regulated expression of Notch receptors and
their ligands in PDAC [20]. We have shown that down-regulation
of Notch-1 using specific siRNA was correlated with decreased
proliferative rates, increased apoptosis, reduced migration, and
decreased invasive properties of pancreatic cancer cells [21,22].
Recently, it has been found that active Notch signaling can
synergize with K-ras in PanIN initiation and progression to invasive
adenocarcinoma [8,23]. Inhibition of Notch signaling pathway
resulted inthe inhibition of tumorprogression ina mouse model (K-
ras, p53 L/+ mice) of PDAC [24]. More recently, Mazur et al.
found that deficiency of Notch-2 stops PanIN progression, prolong
survival through inhibition of Myc signaling in K-ras-driven
pancreatic carcinogenesis [25]. Surprisingly, Notch-1 was recently
found as a tumor suppressor in a model of K-ras-induced PDAC
[18],suggestingthatadditionalstudiesarerequiredtodeterminethe
role of Notch signaling in PDAC.
Notch pathway has been reported to cross-talk with NF-kB, one
of the major transcription factor associated with cell growth and
apoptotic regulatory pathways in pancreatic cancer. Studies from
our group revealed that Notch signaling could induce NF-kB
activity in pancreatic cancer [21]. Recently, it was shown that NF-
kB pathway is required for the development of tumors in a mouse
model (K-ras, p53 L/L mice) of lung adenocarcinoma [26].
Moreover, it was found that genetic deletion of the NF-kB subunit
p65 in a K-ras-induced lung cancer mouse model reduced lung
tumorigenesis in the presence and in the absence of the tumor
suppressor p53 [27]. However, it is largely uncertain whether NF-
kB is necessary for K-ras-induced PDAC progression.
In the present study, we assessed the molecular alterations in
mouse tumors developed in the compound transgenic mice with
activated K-ras and Ink4a/Arf deficiency. Here, we show, for the
first time, that deletion of Ink4a/Arf in K-ras expressing mice
leads to PDAC, which is in part mediated through the activation of
Notch and NF-kB signaling pathways. Moreover, we found
alterations in the expression of miR-200 family, which could also
play important roles in tumor development and progression of
PDAC in the compound transgenic mice with activated K-ras and
Ink4a/Arf deficiency.
Results
Notch signaling pathway is highly expressed in Pdx1-
Cre;LSL-K-ras
G12D;Ink4a/Arf mouse
To delineate the mechanistic role of mutated K-ras in the
development and progression of PDAC, we assessed the expression of
Notch pathway in the murine model. In this model, oncogenic K-ras
(Kras
G12D) is knocked-in into its own locus and transcriptionally
silenced due to the insertion of a LoxP-Stop-LoxP element (LSL).
When LSL- Kras
G12D mice are bred with transgenic mice which
express Cre recombinase under the control of the Pdx1 promoter,
expression of Cre recombinase in pancreatic progenitor cells allows
the removal of the floxed transcriptional STOP cassette, leading to
the activation of the oncogenic K-ras allele. In this model, there was
no tumors readily found up to 30 weeks of age in LSL- K-ras
G12D;
Pdx1-Cre (we called KC in this manuscript) mice, consistent with
previous study [13]. We also found no evidence of PDAC in the
Ink4a/Arf; Pdx1-Cre (we called IC in this manuscript) animals up to
an age of 24 weeks, similar to the observation documented by other
groups [13]. However, all 25 mice from LSL- K-ras
G12D;P d x 1 - Cre;
Ink4a/Arf (we called KCI for this manuscript) group were found to
have pancreatic tumors ranging in diameter from 4 to 10 mm
between 45 to 80 days (Fig. 1A). The compound KCI mice with
tumors became moribund (Fig. 1A, survival curve). The tumors were
confirmed by histopathologic examination (Fig. 1B). The Ki-67, a
known proliferation marker, was highly expressed in KCI pancreatic
tumors (Fig. 1B). It has been reported that Notch signaling pathway
has critical roles in the development and progression of pancreatic
cancer. Therefore, we assessed the expression of Notch genes in these
transgenic mice tissues. It is important to note that we focused our
studiesonthecleavedNotchbecauseitistheactivefunctionalformof
Notch. Therefore, Notch in our all figure legends means active
cleaved Notch. We found that Notch signaling was activated in the
tumors of KCI mice when compared with the pancreata of KC and
IC mice, respectively (Fig. 1C, D). The expression of Notch-2 and
Notch-4 was up-regulated both at the mRNA and protein levels in
KCI mice. However, Notch-1 expression showed no change and
Notch-3 expression was increased only at the mRNA level in the
tumors of KCI mice, suggesting that roles of Notch-2, and Notch-4
couldbemoreimportantinprogressionofpancreaticcancer.Wealso
found that all five Notch ligands were up-regulated in the tumors
derived from the KCI mice (Fig. 2A, B). To confirm these results, we
evaluated the expression of Notch downstream genes such as Hes-1
and Hey-1. We found that the expression of Hes-1 and Hey-1 was
increased in the tumors of KCI mice (Fig. 2A, B), which was expected
based on up-regulated expression of Notch-2, Notch-4 and their
ligands.
NF-kB DNA binding activity was activated in KCI mice
tissue
NF-kB has been reported to cross-talk with Notch pathway
[28]. We have reported earlier that Notch-1 can up-regulate NF-
kB DNA binding activity in pancreatic cancer [22]. Therefore, we
investigated whether the downstream effect of Notch up-regulation
could be mechanistically associated with the activation of NF-kB
pathway in the tumors of these animals. It is well known that the
NF-kB family is composed of homo- and heterodimers of Rel
proteins; NF-kB1 (p50); NF-kB (p52), RelA (p65), RelB, and c-Rel
(Rel). NF-kB (p50/p65) is a ubiquitous, constitutive and inducible
heterodimer. In general, the DNA binding activity of NF-kB
traditionally refers to the p50/p65 (p50/RelA) heterodimer-
mediated binding to the DNA, and it is a known regulator of
cell survival and anti-apoptosis signaling. In the nucleus, the p65
NF-kB subunit is a strong activator of a wide variety of genes;
therefore, we assessed the nuclear expression of p65 protein by
immunohistochemistry. Nuclear proteins from the tumors ob-
tained from the transgenic mice were also subjected to NF-kB p65
ELISA, and NF-kB p65 DNA-binding activity as measured by
EMSA. The results showed that the NF-kB p65 activity as assessed
by ELISA, and the NF-kB p65 DNA binding activity was
activated in tumors derived from the compound KCI mice
(Fig. 2C, D). These results showed an increased nuclear
accumulation of the p65 in the tumors of KCI mice, suggesting
that both activation of K-ras and Ink4a/Arf deficiency are
required for enhanced NF-kB activation. Moreover, immuno-
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nuclear compartment in the tumor tissues of KCI mice (Fig. 2D).
NF-kB downstream genes are activated in KCI mice
It has been reported that Notch pathway stimulates NF-kB
activity in cervical cancer cells by associating with the IKK
signalosome through IKKa [29]. Previous study has shown that
Notch pathway regulates the IKKa expression in pancreatic
cancer [30]. Thus, we investigated the expression of IKK protein
in the tumors of KCI mice. We found that all IKK family
members such as IKKa, IKKb and IKKc were activated in the
tumors of KCI mice (Fig. 3A). To further explore the effects of NF-
kB activation, we examined the expression levels of certain NF-kB
target genes including COX-2, cyclin D1, MMP-9, MMP-2, Bcl-2,
c-myc, and survivin by real-time RT-PCR and western blotting,
respectively, using the tumor tissues obtained from the compound
KCI transgenic animals. Real-time RT-PCR and western blot
analysis showed that the expression of these genes was activated in
the tumors of KCI mice (Fig. 3A, B). We also found that the
expression of Stat3 was activated in the tumors form KCI mice
(data not shown). It is well known that these genes play critical
roles in cell growth, invasion and metastasis. Therefore, these
results further support the role of NF-kB in tumor growth and
progression in the compound KCI mice.
The miRNA-200 family was down-regulated in KCI mice
The miR-200 family have been found to regulate Notch
signaling pathway [31]. The miR-200 family has five members:
Figure 1. Notch receptors are highly expressed in KCI mice. A, Top left panel: Tumor incidence in KCI mice (N.25). Control mice: KC and IC
mice. Top right panel: Average length of tumors in KCI mice (N.20). Bottom panel: Kaplan-Meier pancreatic tumor-free survival curve for KCI mice
and control animals. Control mice: combinations of KC and IC mice. B, Top panel: Microscopic examination of tumors derived from the KCI mice
composed of cells which are forming ducts at places (red arrows). Focally tumor cells are in sheets. Cells are large, highly atypical, with large,
pleomorphic nuclei and prominent 2–3 nucleoli (yellow arrows) per cell. Cytoplasm is eosinophilic with pale eosinophilic inclusions (green arrows)i n
few cells giving a rhabdoid feature to the cells. Surrounding stroma shows spindled cells with elongated nuclei (black arrows) and scattered
inflammatory infiltrate comprising of neutrophils, lymphocytes and few plasma cells. Bottom panel: Ki-67 was highly expressed in tumors obtained
from the KCI mice as assessed by immunohistochemistry. C, Notch signaling pathway was up-regulated at mRNA level as assessed by Real-time RT-
PCR in tumors derived from the KCI mice. D, Notch pathway was highly expressed in tumors derived from the KCI mice as assessed by western
blotting analysis and immunohistochemistry, respectively.
doi:10.1371/journal.pone.0020537.g001
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found that Notch-1 could be one of the target genes of miR-200
family (miR-200b, miR-200c) because over-expression of these
miRNAs significantly inhibited Notch-1 expression in prostate
cancer [31] and pancreatic cancer (unpublished data). To address
whether miR-200 family is involved in the tumors of KCI mice
which showed high expression of Notch (Notch-2 and 4) signaling
pathway, we investigated the expression of miR-200 family. As
expected, the expression of miR-200a, miR-200b and miR-200c
was significantly decreased in the tumors of KCI mice (Fig. 3C).
These results suggest that the tumors developed in the compound
mice could show aggressive behavior such the acquisition of
epithelial-to-mesenchymal transition (EMT) phenotype, and thus
we have further investigated the molecular make-up of the tumors
derived from the compound KCI transgenic mice as detailed
below.
Evidence of EMT phenotype in the tumors derived from
the compound KCI transgenic mice
Recently many studies have shown that the miR-200 family
regulates EMT by targeting zinc-finger E-box binding homeo-
box 1 (ZEB1) and ZEB2. EMT is a process by which epithelial
cells undergo remarkable morphological changes characterized
by a transition from epithelial cobblestone phenotype to
elongated fibroblastic phenotype. Our previous studies have
shown that miR-200a, miR-200b, and miR-200c were down-
regulated in gemcitabine-resistant pancreatic cancer cells,
consistent with the observed EMT phenotype [32,33]. Further-
more, we have shown that miR-200 family regulates the
expression of ZEB1, slug, E-cadherin, and vimentin, and thus
suggested the re-expression of miR-200 could be useful for the
reversal of EMT phenotype to mesenchymal-to-epithelial
transition (MET), which has been partly documented in our
recent publication [34]. Since we found low expression of miR-
200 family in the tumors of KCI mice, we assessed the EMT
markers to investigate whether the tumors in the KCI mice
underwent EMT or not. We found loss of E-cadherin expression
and elevated expression of vimentin and ZEB2 in the tumors of
KCI mice although the expression of ZEB1 showed modest
increase (Fig. 3D), suggesting that the expression of these factors
may be important to induce EMT phenotype in the tumors of
the KCI mice, which appears to be consistent with the
aggressive behavior of the tumors developed in the compound
KCI transgenic mice.
Figure 2. The expression of Notch ligands and NF-kB is upregulated in KCI mice. A, The expression of Notch ligands and Notch
downstream genes was increased at mRNA level as assessed by Real-time RT-PCR in tumors derived from the KCI mice. B, The expression of Notch
ligands and Notch downstream genes was highly expressed in tumors derived from the KCI mice as assessed by western blotting analysis. C, NF-kB
p65 activity was increased in tumors derived from the KCI mice by ELISA. D, Left panel, NF-kB p65 DNA-binding activity is increased in tumors derived
from the KCI mice as assessed by EMSA. Right panel, phospho-p65 was highly expressed in tumors obtained from the KCI mice as assessed by
immunohistochemistry.
doi:10.1371/journal.pone.0020537.g002
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growth in a mouse PDAC cell line
To further assess the potential role of Notch pathway in
pancreatic cancer, we used Rink-1 cell line which was derived
from the KCI pancreatic tissues and studied the effects of
inhibitors of Notch pathway. Previous studies have shown that
Rink-1 cells exhibited rapid growth in vitro and formed tumors in
nude mice [14]. Since Notch signaling is activated via the activity
of c-secretase, several forms of c -secretase inhibitors including
DAPT and L-685,458 have been used to inactivate Notch
pathway. Therefore, we determined the cell viability of Rink-1
cells treated with GSI by the MTT assay, and the data are
presented in Figure 4A. The treatment of Rink-1 cells for 72 hours
with DAPT, and L-685,458 resulted in cell growth inhibition. To
determine which Notch receptor could be an effective therapeutic
target for pancreatic cancer, the effect of Notch 1–4 siRNA on cell
growth of the pancreatic cancer cells was examined. The efficacy
of GSI and Notch siRNA for knockdown of Notch protein was
confirmed through western blotting. We observed that Notch
protein level was barely detectable in GSI treated or Notch siRNA
transfected cells (Fig. 4B). Very interestingly, only inactivation of
single Notch receptor did not significantly inhibit cell growth
(Fig. 4A). These results suggest that inactivation of multiple Notch
receptors by GSI are good way to treat PDAC. To confirm this
conclusion, we tested the expression of Notch target genes in Rink-
1 cells treated with GSI or Notch siRNA. Because only Notch-2
and Notch-4 siRNA slightly inhibited cell growth, we detected the
expression of Notch target genes in Rink-1 cells treated with these
two siRNAs. As we expected, we found that GSI inhibited the
expression of Notch target genes including Hes-1, Survivin, Bcl-2,
c-myc, uPA to more degree, compared to Notch-2 siRNA or
Notch-4 siRNA transfection (Fig. 4C). Therefore, we used GSI in
the following experiments. Next, we tested the effects of treatment
on cell viability by clonogenic assay. GSI treatment resulted in a
significant inhibition of colony formation of Rink-1 cells when
compared with control (Fig. 5A). Overall, the results from
clonogenic assay were consistent with the MTT data, suggesting
that the inactivation of Notch pathway could inhibit cell growth of
Rink-1 cells.
Inhibition of Notch pathway caused apoptotic cell death
in Rink-1 cell line
Next, we investigated whether the overall growth inhibitory
effects of GSI are in part due to induction of apoptosis, which was
examined by using an ELISA-based assay. These results provided
convincing data that GSI induced apoptosis in Rink-1 cell line
(Fig. 5A). To confirm these results, we also used annexin V-FITC
method to detect the apoptosis induced by GSI for which Rink-1
Figure 3. The expression of Notch target genes is increased in KCI mice. A, Western blot analysis showing the up-regulated expression of
IKK, p65, and NF-kB downstream genes in tumors derived from KCI mice. B, Real-time RT-PCR showing increased expression of NF-kB downstream
genes such as survivin, cyclin D1, Bcl-2, C-myc, MMP-2, and MMP-9 in the tumors derived from the KCI mice. C, The expression of miR-200 family was
down-regulated in the tumors of the KCI mice as assessed by real-time RT-PCR. D, Real-time RT-PCR showing decreased expression of E-cadherin, and
increased expression of vimentin, and a modest increase in the expression of ZEB1 whereas a 30-fold increased expression of ZEB2 in tumors derived
from the KCI mice.
doi:10.1371/journal.pone.0020537.g003
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annexin V-FITC and PI, FACS analysis was used to distinguish
and quantitatively determine the percentage of dead, viable and
apoptotic cells after treatment. We found that the percentage of
apoptotic cells increased from 10% in the control to 28–33% in
Rink-1 cells after GSI treatment (Fig. 5A). These results provided
convincing data showing that inactivation of Notch pathway could
induce apoptosis in Rink-1 pancreatic cancer cells.
Inhibition of Notch pathway decreased cancer cell
migration and invasion
Notch pathway is believed to be critically involved with the
processes of tumor cell invasion and metastasis. Previous studies
have shown that pancreatic tumors arising in the compound KCI
mice have extensive invasion of adjacent organs, including the
duodenum, stomach, liver, and spleen [13]. In order to better
understand whether Notch pathway has a critical role in invasion,
we tested the effects of inactivation of Notch pathway on cancer
cell invasion. We found that GSI treated cells showed a lower level
of penetration through the matrigel-coated membrane compared
with the control cells. The value of fluorescence from the invaded
Rink-1 cancer cells was decreased about 5–7 fold compared with
that of control cells (Fig. 5B). In order to further examine the effect
of GSI on cell migration and invasion, we conducted wound
healing assay in Rink-1 cells. The results show that GSI treatment
inhibited the capacity of wound healing in Rink-1 cells (Fig. 5B),
suggesting that GSI can inhibit cell migration and invasion. These
results suggest a direct role of Notch signaling in Rink-1 cancer cell
migration and invasion, and these results are consistent with
aggressiveness of tumors developed in the compound KCI
transgenic animal.
Inhibition of Notch pathway decreased NF-kB DNA-
binding activity
We investigated whether the downstream effect of Notch-1
down-regulation was mechanistically associated with the NF-kB
pathway. Nuclear proteins from GSI treated cells were subjected
to analysis for NF-kB p65 DNA-binding activity as measured by
Figure 4. Inhibition of Notch pathway by Notch siRNA or GSI inhibited Rink-1 cell growth. A, Left panel, Inhibition of Rink-1 cell growth
by Notch 1–4 siRNA tested by MTT assay. The results were plotted as means 6 SD of three separate experiments having six determinations per
experiment for each experimental condition. Middle and Right panel: L-685,458 and DAPT were c-secretase inhibitors (GSI), which prevent the
cleavage of the Notch receptor, blocking Notch signal transduction. GSI significantly inhibited Rink-1 cell growth. Cells were seeded in 96-well plates
at 5,000 cells per well and treated with GSI for 72 hours. After treatment, cell densities were determined by MTT assay. Each value represents the
mean 6 SD (n=6) of three independent experiments. *P,0.05, compared to the control. B, The expression of Notch pathway was down-regulated in
Rink-1 cells treated with GSI or transfected with Notch 1–4 siRNA as assessed by western blotting analysis. C, The expression of Notch target genes
was down-regulated in Rink-1 cells treated with GSI or transfected with Notch-2 siRNA or Notch-4 siRNA as assessed by as assessed by real-time RT-
PCR.
doi:10.1371/journal.pone.0020537.g004
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kB p65 DNA-binding activity compared to control (Fig. 5C).
These results provided evidence in support of a mechanistic
crosstalk between Notch and NF-kB in pancreatic cancer.
Furthermore, we also found that GSI inhibited NF-kB down-
stream gene expression, such as Survivin, Bcl-2, c-myc, and uPA
(Fig. 5D).
Over-expression of miR-200b inhibited the cell growth
through Jagged ligands
Recently, it has been reported that miR-200 family members
target Notch pathway components, such as Jagged-1 [35,36]. In
order to examine whether miR-200 family regulate Notch
pathway, we transfected miR-200b precursor into Rink-1 cells.
We confirmed that the transfection of miR-200b precursor
increased the relative level of miR-200b in Rink-1 cells (Fig. 6A).
Over-expression of miR-200b decreased the relative mRNA levels
of Jagged-1, Jagged-2 and their target genes by real time RT-PCR
assay (Fig. 6A). The data from western blot analysis demonstrated
that over-expression of miR-200b decreased the relative protein
levels of Jagged-1 and its target gene such as Hes-1, Hey-1, and
Bcl-2 (Fig. 6B). Moreover, we found that over-expression of miR-
200b inhibited cell growth in Rink-1 cells (Fig. 6B). Next, we
detected whether inhibition of Jagged-1 could inhibit cell growth.
Jagged-1 siRNA significantly decreased the expression of Jagged-1
and its target Hes-1 and Hey-1 at mRNA and protein levels
(Fig. 6C). Furthermore, we found that inhibition of Jagged-1 by
Jagged-1 siRNA inhibited the Rink-1 cell growth (Fig. 6C),
suggesting that Jagged-1 could be a potential target for pancreatic
cancer.
Figure 5. GSI induced apoptosis, inhibited migration and invasion in Rink-1 cells. A, Top, Left panel: Cell survival of Rink-1 cells treated
with GSI. Cells treated with GSI for 72 hours were evaluated by the clonogenic assay. Photomicrographic difference in colony formation in cells
untreated and treated with GSI. Right panel: There was a significant reduction in the colony formation in Rink-1 cells treated with GSI compared with
control cells. P values represent comparisons between cells treated with GSI and control using the paired t test. Bottom, Left panel: Characterization
of apoptosis was carried out after propidium iodide (PI) and Annexin V-FITC staining with apoptosis detection kit followed by flow cytometric analysis
after 48 h of GSI treatment of Rink-1 cells. The percentage of apoptotic cells increased from 10% in the control to 28–33% in GSI treated cells. Right
panel: GSI induced apoptosis in Rink-1 cells. Rink-1 cells were exposed to GSI for 72 hours. Apoptosis was measured by Histone DNA ELISA. Values are
reported as mean 6 SD. *P,0.05, compared to the control. B, Top, Left panel, Invasion assay using GSI treated cells showing low penetration of cells
through the Matrigel-coated membrane, compared with control cells. Right panel: The graphs showing the value of fluorescence from the invaded
Rink-1 cells. The values indicate the comparative amount of invaded Rink-1 cells. Bottom, Wound healing assay was conducted to assess the
capacity of cell migration. GSI treatment decreased the cell migration in Rink-1 cells. C, GSI inhibited the NF-kB DNA binding activity in Rink-1 cells as
assessed by EMSA. D, Real-time RT-PCR and western blot analysis showed that L-685,458 inhibited the expression of Survivin, c-myc, Bcl-2, and uPA
genes.
doi:10.1371/journal.pone.0020537.g005
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PDAC is the fourth leading cause of cancer-related deaths in the
United States [1]. Although some progress in chemotherapy,
radiation therapy, and surgical technique, the overall survival rate
for five years is less 4% of all patients diagnosed with PDAC [1].
These disappointing outcomes suggest that new and alternative
approaches to the understanding the mechanisms of PDAC
progression is critically needed. Transgenic mice are good models
to identify the pathogenic role of specific gene mutations and core
signaling pathways associated with pancreatic cancer.
It has been known that K-ras mutations are observed in 80%–
90% of pancreatic cancer. Oncogenic K-ras is involved in the
initiation or early stages in the development of PDAC.
Therefore, the conditional KC mice are considered good tools
for mechanistic studies of pancreatic cancer progression. Since
KC mice mimic slow progression from PanIN to invasive cancer
in around 12–15 months [6,37], but the KC mice bred with
many other transgenic mice showed rapid development the
PDAC. For example, Smad4/Dpc4 haploinsufficiency short-
ened the life span of KC mice to median survival of
approximately 8 months [10]. LSL- K-ras
G12D;P d x 1 - C r e ;
Trp53R mice have a dramatically shortened median survival
of approximately 5 months [6]. The median survival time of KC
mice with LKB1 heterozygosity was 4.5 months [11]. PTEN
haploinsufficiency significantly shortened the life span of KC
mice to a median survival of around 3.5 months [9]. The p21
heterozygosity made the KC mice with a median survival of 2.5
months [11]. One mouse model having activated K-ras and
Ink4a/Arf deficiency had median survival of 2 months [13].
Therefore, for the present study, we used the compound KCI
mice (activated K-ras and Ink4a/Arf deficiency) to investigate
the mechanisms of pancreatic cancer progression.
Pancreatic cancer has been shown to have deregulated Notch
signaling pathway. Although Notch pathway has been reported
to have a tumor suppressive role in certain specific condition
[18], the majority of studies show that the activated Notch
pathway contributes to PDAC tumorigenesis [19,25,38–40].
The high level expression of Notch receptors, Notch ligands and
Notch target genes have also been observed in human
pancreatic cancer [19–21,38–40]. Notch activity is required
for TGF-a-induced acinar-to-ductal transition and prevention
of Notch activation by GSI prevents acinor-to-ductal metaplasia
in TGF-a-treated cells [41]. It has been reported that GSI
inhibited tumor progression in LSL-K-ras
G12D; Pdx1-Cre;
Trp53R mouse model of PDAC [24]. Moreover, it has been
found that Notch signaling was downstream of K-ras gene in
pancreatic cancer [23,42–44]. In this study, we used the
Figure 6. The miR-200b inhibited Rink-1 cell growth and Jagged-1 expression. A, Left panel, Re-expression of miR-200b was established in
Rink-1 cells by transfection with its precursor. Middle panel, Re-expression of miR-200b did not regulate the expression of Notch receptors in Rink-1
cells. Right panel, Re-expression of miR-200b regulated the expression of Jagged-1 and Jagged-2 mRNAs in Rink-1 cells. B, Left and middle panel, Re-
expression of miR-200b inhibited the expression of Jagged-1 target genes at mRNA and protein levels in Rink-1 cells. Right panel, Re-expression of
miR-200b inhibited Rink-1 cell growth test by MTT assay. C, Left and middle panel, Jagged-1 siRNA inhibited the expression of Jagged-1 target gene
Hes-1 and Hey-1 at mRNA and protein levels in Rink-1 cells. Right panel, Jagged-1 siRNA inhibited Rink-1 cell growth test by MTT assay.
doi:10.1371/journal.pone.0020537.g006
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human pancreatic cancer to determine whether Notch signaling
could be required for the development of PDAC. Indeed, we
found over-expression of Notch signaling pathway in the tumors
of KCI mice. The molecular explanation for the high expression
of Notch in the tumors of KCI mice could be due to Ink4a/Arf
deficiency. Furthermore, inhibition of Notch pathway by GSI in
murine pancreatic cancer cell line Rink-1 inhibited cell growth,
migration, and invasion, suggesting that Notch signaling
pathway appears to be a viable therapeutic target for PDAC,
which has been an active area of drug development.
The cross-talk between Notch and NF-kB in PDAC has been
found in human cancer including pancreatic cancer
[22,28,45]. It was found that Notch pathway stimulated NF-
kB activity in cervical cancer cells by associating with the IKK
signalosome through IKKa [29,46]. We have reported that
N o t c hp a t h w a yc a nr e g u l a t eN F - kB activity in pancreatic
cancer [21,22]. In the present study, we found that NF-kBw a s
activated in the tumors of KCI mice, suggesting that the
downstream effect of Notch pathway up-regulation was
mechanistically associated with the activation of NF-kB
signaling pathway in the tumors developed in the compound
KCI transgenic mice. Moreover, activated NF-kB-regulated
genes which are involved in cell growth, apoptosis, migration,
and invasion are also activated. Furthermore, GSI inhibited
NF-kB activity and its downstream genes in Rink-1 cells.
These results demonstrate the importance of NF-kB signaling
and provide a basis to consider the pharmacological inhibition
of the NF-kB for the treatment of PDAC, which has also been
an active area of drug development.
In recent years, microRNAs (miRNAs) have been reported to
participate in Notch pathway regulation in pancreatic cancer [47].
One important miRNA is miR-200 family, which is involved in
the regulation of EMT, stem cells and the regulation of Notch
pathway [35,36]. The miR-200 family has five members: miR-
200a, miR-200b, miR-200c, miR-141 and miR-429. Our previous
study has shown that Notch pathway could be one of the target of
miR-200b [31]. Consistent with this notion, we found loss of miR-
200a, miR-200b, and miR-200c expression in the tumors of KCI
mice, suggesting that activated Notch pathway could also be due
to the loss of expression of miR-200 family. Over-expression of
miR-200b decreased the expression of Jagged ligands and Notch
target gene such as Hes-1, Hey-1, and Bcl-2, leading to cell growth
inhibition. Moreover, we found that over-expression of miR-200b
inhibited cell growth in Rink-1 cells (Fig. 6B). Most interestingly,
recent studies have shown that the miR-200 family regulates EMT
by targeting ZEB expression. We have reported earlier that miR-
200a, miR-200b, and miR-200c are down-regulated in gemcita-
bine-resistant pancreatic cancer cells, which have high expression
of Notch pathway and contributed to the acquisition of EMT
phenotype [33,34]. The acquisition of EMT has been documented
to be involved with invasion and metastasis, and thus our data on
the loss of miR-200 suggest that the EMT phenotypic tumors in
our compound mice, and that the tumors in these animals are
invasive and metastatic compared to pancreata with K-ras
activation or Ink4a/Arf loss alone.
Figure 7. The schematic representation of our proposed molecular mechanism involved in the development and progression of
tumors in the compound KCI transgenic mice.
doi:10.1371/journal.pone.0020537.g007
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by which the tumors developed in the compound KCI transgenic
mice with activated K-ras and Ink4a/Arf deficiency is in part due
to the loss of miR-200 family, which leads to the activation of
Jagged/Notch and NF-kB signaling pathway, resulting in the up-
regulation of NF-kB target genes, such as MMP-9, c-myc,
survivin, Bcl-2, cyclin D1, and COX-2 as summarized in the
cartoon diagram (Fig. 7) and contributes to tumor aggressiveness.
Although we have demonstrated the loss of miR-200, and the
activation of Notch and NF-kB signaling pathway in the current
animal model; however, there maybe other genetic alterations
causing tumor aggressiveness in this compound mice with
activated K-ras and Ink4a/Arf deficiency, suggesting that further
in-depth studies are needed to investigate the precise molecular
mechanism of tumor progression in this mouse model. Moreover,
novel strategies for the re-expression of miR-200 and its
consequence could be tested in this animal model, which would
help in the rational drug design in addition to Notch and NF-kB
targeted drugs for the treatment of human PDAC for improving
the overall survival of patients diagnosed with this devastating
disease.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Any
animal found unhealthy or sick were promptly euthanized. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of Wayne State University institutional Users Animal
Care Committee (Permit Number: A-10-03-08).
Mouse Model
The LSL-K-ras
G12D strain was bred to the following strains:
Pdx1-Cre, INK4a/Arf
lox/lox as previously described [14,48].
Pancreata were collected and processed for further analysis.
Genotyping
For genotyping, genomic DNA was extracted from tail cuttings
using the REDExtract-N-Amp Tissue PCR kit (Sigma-Aldrich, St.
Louis, Missouri). Three PCR reactions were carried out for each
animal to investigate the presence of the oncogenic K-ras, p16 and
Pdx1-Cre transgenes, respectively.
Cell lines
Rink-1 murine pancreatic tumor cell line was generated from
the pancreatic tissue obtained from LSL- Kras
G12D; Pdx1-Cre;
Ink4a/Arf mice as previously described [13,14].
Histopathology and immunohistochemistry
Histopathologic analysis of pancreata was carried out. The
expression of Ki-67, Notch, and phospho-p65 was assessed in
histological sections of tumors as described before [49].
Real-time reverse transcription-PCR analysis for gene
expression studies
The total RNA from animal tissues was isolated by Trizol
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocols. The primers used in the PCR reaction were described
earlier [21,22,31,50]. Real-time PCR amplifications were per-
formed as described earlier [21].
Western blot analysis
The animal tissues were homogenized and sonicated in 62 mM
Tris-HCl and 2% SDS. In another set of experiments, cytoplasmic
and nuclear proteins were also extracted. The proteins were used
for western blotting as described earlier [21].
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from animal tissues and
electrophoretic mobility shift assay was done by incubating
10 mg nuclear extract with IRDye-700-labeled NF-kB oligonucle-
otide as described earlier [22].
NF-kB p65 DNA-binding activity assay
Nuclear extracts (5 mg) was used to determine p65 DNA-
binding activity using an enzyme-linked immunosorbent assay
(ELISA)-based assay according to the manufacture’s instructions
(Active Motif TransAM).
TaqMan miRNA real-time reverse transcription–PCR
To determine the expression of miRNAs in transgenic mice
tissues, we used TaqMan miRNA assay kit (Applied Biosystems)
following manufacturer’s protocol. Total RNA was extracted, and
5 ng from each sample were reverse transcribed as described
earlier [32]. Real-time PCR reactions were then carried out in a
total volume of 25 mL reaction mixture using Smart Cycler II
(Cepheid) as described earlier [32].
Cell invasion assay
The invasive activity of the cells was tested using the BD
BioCoat Tumor Invasion Assay System (BD Biosciences, Bedford,
MA) as described earlier [22].
Wound healing assay
Wound healing assay was conducted to examine the capacity of
cell migration. Briefly, the wound was generated in the cells with
90–95% confluent by scratching the surface of the plates with a
pipette tip. The cells were then incubated in the absence and
presence of GSI for 24 h, and then photographed with a Nikon
microscope.
siRNA, miRNA and transfection experiments
Cells were transfected with 100 nmol/L of Notch-1, Notch-2,
Notch-3, Notch-4, Jagged-1 siRNA or control siRNA (Santa Cruz)
as well as 20 nmol/L of miR-200b (Ambion, Austin, TX) using
DharmaFECT3 siRNA transfection reagent (DHARMACON,
Lafayette, CO) as previously described [31].
Densitometric and statistical analysis
The statistical significance of differential findings between
experimental groups and control groups was statistically evaluated
using GraphPad StatMate software (GraphPad Software, Inc., San
Diego, CA). P values lower than 0.05 were considered statistically
significant.
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